The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts

Expert Opinion on Biological Therapy

Volumn 12, Issue 6, 2012, Pages 783-793

  Stockfleth, Eggert ^a   Meyer, Thomas ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Catechin; Genital warts; Green tea; Human papillomavirus; Polyphenol

Indexed keywords

BETA INTERFERON; CELL ADHESION MOLECULE; DICHLOROACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GAMMA INTERFERON; GREEN TEA EXTRACT; IMIQUIMOD; INTERLEUKIN 2; PLACEBO; PODOPHYLLIN; PODOPHYLLOTOXIN; POLYPHENON E; TRICHLOROACETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BURNING SENSATION; CELL CYCLE ARREST; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DRUG CLEARANCE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELECTROSTIMULATION THERAPY; ELECTROSURGERY; EPITHELIUM CELL; ERYTHEMA; EXCISION; EXTERNAL GENITAL WART; GENE EXPRESSION; HUMAN; INTERMETHOD COMPARISON; LIFE CYCLE; LOW LEVEL LASER THERAPY; NONHUMAN; OINTMENT; PAIN; PAPILLOMA; PHOTODYNAMIC THERAPY; PRURITUS; SYSTEMIC DISEASE; TOPICAL TREATMENT; ULCER; VIRUS INHIBITION; VIRUS REPLICATION; WART VIRUS;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIVIRAL AGENTS; CATECHIN; CHEMISTRY, PHARMACEUTICAL; CONDYLOMATA ACUMINATA; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; OINTMENTS; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; TREATMENT OUTCOME;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84861322347     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.676036     Document Type: Article

References (78)

1. Van Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-168
2. Health Protection Agency UK (2010). Available from: http://www.hpa.org. uk/webc/HPAwebFile/HPAweb-C/1215589013442
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8
4. Storey A, Pim D, Murray A, et al. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988;7:1815-1820
5. Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus types 6, 16, and 18 DNAs on immortilization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 1989;86:563-567
6. Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs correspond to their association with cervical carcinoma. J Virol 1989;63:159-164
7. Gross G, Ikenberg H, Petry KU, et al. Condylomata acuminata und other HPV-associated disease pictures of the genitals, anus and urethra. J Dtsch Dermatol Ges 2008;6:153-162
8. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: Diagnosis, treatment and prevention. Clin Infect Dis 2002;35(Suppl 2):S210-224
9. British association of sexual health and HIV (BASHH). UK national guideline on the management of anogenital warts, 2007. Available from: www.bashh.org/guidelines
10. Centers for disease control and prevention (CDC): 2010 STD treatment guidelines. MMWR 2010;59:No RR-12. Available from: www.cdc.gov/std/treatment/ 2010
11. wmf-Leitlinie 059/001 condylomata acuminata und andere HPV-assoziierte krankheitsbilder von genitale. Anus und Harnrohre. Available from: http://www. awmf.org/uploads/tx-szleitlinien/059-001-S1-Condylomata-acuminata-und-andere- HPV-assoziierte-Krankheitsbilder-des-Genitale-und-der-Harnroehre-07-2006-07- 2011-01.pdf.
12. AWMF-Leitlinie 059/001 Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder von Genitale, Anus und Harnrohre. Available from: http://www. awmf.org/uploads/tx-szleitlinien/059-001-S1-Condylomata-acuminata-und-andere- HPV-assoziierte-Krankheitsbilder-des-Genitale-und-der-Harnroehre-07-2006-07- 2011-01.pdf 12. Beutner KR, Wiley DJ. Recurrent external genital warts. a literature review. Papillomavirus Rep 1997;8:69-74
13. Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res 2011;64:100-104
14. VEREGEN (sinecatechins) Ointment, 15%. Available from: http://www. veregen.com/veregenrx/pdf/VER051-Promo-PI.pdf
15. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) 2009;2:514-517
16. Ju J, Lu G, Lambert JD, et al. Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol 2007;17:395-402
17. Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429-439
18. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (ECGC): Mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011;82:1807-1821
19. Tzellos TG, Sardeli C, Lallas A, et al. Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: A systematic review and meta-analysis. JEADV 2011;25:345-353
20. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-774
21. Stanley M. Immune responses to human papilloma viruses. Indian J Med Res 2009;130:266-276
22. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-15
23. Frazer IH. Interaction of human papillomaviruses with the host immune system: A well developed relationship. Virology 2009;384:410-414
24. Zur Hausen H. Papillomavirus and cancer: From basic research studies to clinical application. Nat Rev Cancer 2002;2:342-350
25. Hoppe-Seyler F, Butz K. Cellular control of human papillomavirus oncogene transcription. Mol Carcinog 1994;10:134-141
26. Dyson N, Howley PM, Munger K. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-936
27. Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9
28. Gage J, Myers C, Wettstein F. The E7 proteins of the non-oncogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma binding and other properties. J Virol 1990;64:723-730
29. Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin proteasome pathway. Cancer Res 1996;56:4620-4624
30. Banerjee NS, Genovese NJ, Noya F, et al. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S-phase in postmitotic, differentiated human keratinocytes. J Virol 2006;80:6517-6524
31. Genovese NJ, Banerjee NS, Broker TR, et al. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J Virol 2008;82:4862-4873
32. Thomas M, Banks L. Human papillomavirus E6 interactions with Bak are conserved among E6 proteins from high and low risk HPV types. J Gen Virol 1999;80:1513-1517
33. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: Infection with high-risk vs low-risk human papillomaviruses. APMIS 2010;118:471-493
34. Demers GW, Foster SA, Halbert CL, et al. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 1994;91:4382-4386
35. Zerfass-Thome K, Zwerschke W, Mannhardt B, et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-2330
36. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005;17:251-264
37. Li S, Labrecque S, Gauzzi MC, et al. The human papillomavirus (HPV)-18 E6 oncoprotein physically interacts with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999;18:5727-5737
38. Katiyar SK, Agarwal R, Wood GS, et al. Inhibition of 12-O- tetradecanoylphorbol-13-acetat-caused tumor promotion in 7,12- dimethybenzanthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea. Cancer Res 1992;52:6890-6897
39. Mukthar H, Katiyar SK, Agarwal R. Green tea and skin-anticarcinogenic effects. J Invest Dermatol 1994;102:3-7
40. Katiyar SK, Mohan RR, Agarwal R, et al. Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols. Carcinogenesis 1997;18:497-502
41. Mittal A, Piyathilake C, Hara Y, et al. Exceptionally high protection of photocarcinogensis by topical application of (-)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: Relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 2003;5:555-565
42. Meeran SM, Akhtar S, Katiyar SK. Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation. J Invest Dermatol 2009;129:1258-1270
43. Katiyar SK, Matsui MS, Elmets CA, et al. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol 1999;69:148-153
44. Katiyar SK. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch Biochem Biophys 2011;508:152-158
45. Iwakura Y, Nakae S, Saijo S, et al. The roles of IL17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008;226:57-79
46. Katiyar SK. Skin photoprotection by green tea: Antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:234-242
47. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002;42:25-54
48. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: Evidence from Animal Studies. J Nutr 2003;133:S3275-3284
49. Yang GY, Liao J, Kim K, et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998;19:611-616
50. Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007;12:5039-5051
51. Leone M, Zhai D, Sareth S, et al. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003;63:8118-8121
52. Hastak K, Gupta S, Ahmad N, et al. Role of p53 and NFkappaB in epigallocatechin-3-gallate-induced apoptosis in LNCaP cells. Oncogene 2003;22:4851-4859
53. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421
54. Nomura M, Ma W, Chen N, et al. Inhibition of 12-O-tetradecanoylphorbol- 13-acetat-induced NF-kappaB activation by tea polyphenols (-)-epigallocatechin- 3-gallate and theaflavins. Carcinogenesis 2000;21:1885-1890
55. Mauro C, Zazzeroni F, Papa S, et al. The NFkappa B transcription factor pathway as a therapeutic target in cancer: Methods for detection of NFkappa B activity. Methods Mol Biol 2009;512:169-207
56. Gupta S, Hussain T, Mukhtar H. Molecular pathways for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003;410:177-185
57. Masuda M, Suzui M, Weinstein IB. Effects of epigallocartechin-3-gallate on growth, epidermal growth factor receptor signalling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001;7:4220-4229
58. Liang YC, Lin-Shiau SY, Chen CF, et al. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997;67:55-65
59. Sah JF, Sivaprakasam B, Eckert RL, et al. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signalling pathway. J Biol Chem 2004;279:12755-2762
60. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcripts leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010;5:10. doi 10.1186/1750-2187-5- 10
61. Angel P, Karin M. The role of jun, fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-157
62. Dong Z, Ma W, Huang C, et al. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea phenols (-)-epigallocatechin gallate, and theaflavins. Cancer Res 1997;57:4414-4419
63. Cheng W, Dong Z, Valcic S, et al. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 1999;24:79-84
64. Yang CS, Sang S. Lambert JD, et al. bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008;52:S139-151
65. Dvorakova K, Dorr RT, Valcic S, et al. Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemother Pharmacol 1999;43:331-335
66. Gross G, Meyer KG, Pres H, et al. A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. JEADV 2007;21:1404-1412
67. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the Treatment of external genital and perianal warts: A randomized controlled study. Br J Dermatol 2008;158:1329-1338
68. Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial. Obstet Gynecol 2008;111:1371-1379
69. Tatti S, Stockfleth E, Beutner KR, et al. Polyphenon E: A new treatment for external anogenital warts. Br J Dermatol 2010;162:176-184
70. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
71. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-239
72. Maitland JE, Maw R. An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int J STD AIDS 2000;11:268-270
73. Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009;200:233; e1-7
74. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied Podofilox for treatment of genital warts. Lancet 1989;15:831-834
75. Sauerbrei A, Deinhardt S, Zell R, et al. Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010;1:555-557
76. Isaacs CE, Wen GY, Xu W, et al. Epigallocatechin gallate inactivates clinical isolates of Herpes simplex virus. Antimicrob Agents Chemother 2008;52:962-970
77. Nakayama M, Suzuki K, Toda M, et al. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res 1993;21:289-299
78. Song JM, Lee KW, Seong BL. Antiviral effects of catechins in green tea on influenza virus. Antiviral Res 2005;68:66-74